Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623299 | 0.94 | BCL6 (0.37) | BCL6STK17BSTK17ASYKP2RX7 | |
| SCHEMBL13623303 | 0.89 | BCL6 (0.36) | BCL6STK17BSTK17ASYKP2RX7 | |
| SCHEMBL4485009 | 0.88 | BCL6 (0.36) | BCL6STK17BSTK17ASYKP2RX7 | |
| SCHEMBL4353268 | 0.82 | TLR7 (0.40) | TLR7AURKARPS6KB1AKT1CYP3A4 | |
| SCHEMBL4356005 | 0.81 | BCL6 (0.35) | BCL6AURKAJAK3 | |
| SCHEMBL13670011 | 0.80 | BCL6 (0.37) | BCL6 | |
| SCHEMBL13622745 | 0.79 | SYK (0.43) | BCL6STK17BSTK17ASYKP2RX7 | |
| SCHEMBL1027969 | 0.78 | EGFR (0.43) | STK17BSTK17ASYKMETAURKA | |
| SCHEMBL1026903 | 0.77 | STK17B (0.41) | BCL6STK17BSTK17ASYKP2RX7 | |
| SCHEMBL1025626 | 0.77 | SYK (0.42) | BCL6STK17BSTK17ASYKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | BCL6 392/4885STK17B 139/4885STK17A 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.